跳轉至內容
Merck
全部照片(1)

重要文件

1603006

USP

核黄素

United States Pharmacopeia (USP) Reference Standard

同義詞:

(−)-核黄素, 乳黄素, 维生素 B2, 维生素 G

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C17H20N4O6
CAS號碼:
分子量::
376.36
Beilstein:
97825
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

riboflavin

製造商/商標名

USP

mp

290 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

CC1=C(C)C=C(N(C[C@H](O)[C@@H]([C@H](O)CO)O)C(C2=N3)=NC(NC2=O)=O)C3=C1

InChI

1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1

InChI 密鑰

AUNGANRZJHBGPY-SCRDCRAPSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

本产品按照发行药典的发行和规定提供。支持本产品的所有信息,包括安全数据表和任何产品信息传单,都是在发行药典的授权下开发和发布的。如需进一步信息和支持,请访问现行药典网站。

應用

核黄素USP参考标准品用于指定质量测试和分析。

还可用于制备标准、核黄素标准储备溶液,用于根据以下美国药典(USP)各论和通则进行分析、鉴定和性能测试:
  • 核黄素
  • 核黄素片
  • 水溶性维生素制剂
  • 〈481〉 核黄素分析

分析報告

这些产品仅供测试和化验使用。它们不适用于人类或动物,也不能用于诊断、治疗或治愈任何类型的疾病。

其他說明

可能适用相应的销售限制。

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Riboflavin Tablets
United States Pharmacopeia, 41(6), 3870-3870 (2017)
Water-Soluble Vitamins Preparation
United States Pharmacopeia, 45(5) (2021)
Olivier Richoz et al.
Investigative ophthalmology & visual science, 55(9), 5783-5787 (2014-07-24)
When treating peripheral ectatic disease-like pellucid marginal degeneration (PMD), corneal cross-linking with UV-A and riboflavin (CXL) must be applied eccentrically to the periphery of the lower cornea, partly irradiating the corneal limbus. Here, we investigated the effect of standard and
Christine Wittig-Silva et al.
Ophthalmology, 121(4), 812-821 (2014-01-08)
To report the refractive, topographic, and clinical outcomes 3 years after corneal collagen cross-linking (CXL) in eyes with progressive keratoconus. Prospective, randomized controlled trial. One hundred eyes with progressive keratoconus were randomized into the CXL treatment or control groups. Cross-linking
Frederik Raiskup et al.
The ocular surface, 11(2), 65-74 (2013-04-16)
Changes in the biomechanical properties of the human cornea play an important role in the pathogenesis of corneal ectatic diseases. Biomechanical investigation shows significant differences between human ectatic corneas and normal corneas, including decreased stiffness and reduction of collagen crosslinks

文章

Pyridoxine hydrochloride, ≥98% (HPLC); Nicotinamide, ≥98.5% (HPLC); Thiamine hydrochloride, reagent grade, ≥99% (HPLC); Biotin, ≥99.0% (T); Folic acid, analytical standard; Cyanocobalamin (B12), analytical standard; Riboflavin (B2), analytical standard

Pyridoxine hydrochloride, ≥98% (HPLC); Nicotinamide, ≥98.5% (HPLC); Thiamine hydrochloride, reagent grade, ≥99% (HPLC); Biotin, ≥99.0% (T); Folic acid, analytical standard; Cyanocobalamin (B12), analytical standard; Riboflavin (B2), analytical standard

條款

Separation of Pyridoxine; Nicotinamide; Nicotinic acid; Folic acid; (−)-Riboflavin, meets USP testing specifications; L-Ascorbic acid

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務